Ligand Pharmaceuticals Incorporated (FRA:LGDN)

Germany flag Germany · Delayed Price · Currency is EUR
153.00
-4.00 (-2.55%)
Last updated: Feb 20, 2026, 3:49 PM CET
Market Cap3.07B +44.5%
Revenue (ttm)214.13M +64.8%
Net Income41.41M +7.4%
EPS2.12 +0.8%
Shares Outn/a
PE Ratio74.23
Forward PE22.31
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume3
Open157.00
Previous Close157.00
Day's Range153.00 - 157.00
52-Week Range86.00 - 181.00
Betan/a
RSI42.53
Earnings DateFeb 11, 2026

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neurobla... [Read more]

Industry Pharmaceutical Preparations
Founded 1987
Employees 68
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol LGDN
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements